Emerging data on patients who have had a drug-eluting stent (DES) procedure demonstrate
the importance of patient adherence to dual anti-platelet therapy in reducing the
risk of stent thrombosis.
A developing consensus recommends that physicians be part of a broad effort to ensure
that patients are well informed and properly compliant post procedure.*
The Stentplus™ Patient Success Program is the first program of its kind designed
to help the cardiology team meet this challenge in continuing care. The Stentplus™
Program provides tools to help your drug-eluting stent patients—regardless
of stent brand—stay on the dual anti-platelet therapy you prescribe.
Stentplus.com explains the need for compliance and how the Stentplus™ Program
will help you and your patients meet this challenge.
ACC/AHA/SCAI guidelines state "...clopidogrel should ideally be continued up to
12 months in all [drug-eluting stents] stented patients who are not at high risk
of bleeding." For more information about ACC/AHA/SCAI guidelines, click
here.
You are leaving the site.
In order to access the requested information, you will leave the Stentplus™
Web site. Do you wish to continue?
Yes
No
* The American Heart Association, American College of Cardiology, Society for Cardiovascular
Angiography and Interventions, American College of Surgeons, and American Dental
Association (with representation from the American College of Physicians).